Companies › NSRX

NASUS PHARMA LTD (NSRX)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0002029039 · EDGAR filings · Updated 2026-07-28

NASUS PHARMA LTD (NSRX) has reported institutional ownership of 24.1%, with 9 institutional managers holding positions valued at $4.83M per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Filings this week (1)

• 2026-07-28 — Foreign issuer report (6-K) filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-06-22 — Insider transaction reported (Form 4)
• 2026-06-09 — Foreign issuer report (6-K) filed
• 2026-05-26 — Employee-plan registration (S-8) filed
• 2026-05-15 — SCHEDULE 13G filed
• 2026-04-22 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, NASUS PHARMA LTD has 9 institutional holders and institutional ownership of 24.1%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 4 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Related companies

CUE BIOPHARMA (CUE) · ELECTROCORE INC (ECOR) · SPECTRAL AI INC (MDAI) · XBiotech Inc (XBIT) · HYPERION DEFI INC (HYPD) · Senti Biosciences Inc (SNTI)